BPC-157 Australia

BPC-157 Australia. BPC-157 is a synthetic 15-amino-acid pentadecapeptide studied in laboratory research across the soft-tissue, tendon, ligament, gastric and angiogenesis literature — the category benchmark cited in nearly every research-peptide catalogue. The Elite AU Peptides BPC-157 is independently HPLC-tested by Janoshik; the certificate of analysis is published on this page and in the lab-reports library, with the measured number — not a marketing figure — and an independently verifiable Janoshik key.

Available in 5 mg and 10 mg lyophilised vials, AU-domestic, AUD pricing. Every batch is held until the independent HPLC report comes back within our acceptance threshold; nothing is listed without a certificate on file. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption, not a therapeutic good, not TGA-approved.

BPC-157 (CAS 137525-51-0; molecular formula C62H98N16O22, average molecular weight ≈ 1419 g/mol; sequence GEPPPGKPADDAGLV) is a 15-residue pentadecapeptide — Body Protective Compound-157 — a partial sequence derived from research on a stable gastric-juice protective protein. It is one of the most-studied compounds in the research-peptide literature, referenced across tendon and ligament cytoprotection, gastric-mucosal, angiogenic and broader soft-tissue-repair research.

Pathway research on BPC-157 is synthesised in the review by Seiwerth and colleagues (Frontiers in Pharmacology, 2021), which covers its reported interaction with the nitric-oxide system and its VEGFR2-associated angiogenic signalling. The pro-angiogenic mechanism — up-regulation and activation of the VEGFR2–Akt–eNOS axis — was reported by Hsieh and colleagues (Journal of Molecular Medicine, 2017).

In tendon-cell research, Chang and colleagues (Journal of Applied Physiology, 2011) linked BPC-157 to tendon-fibroblast outgrowth, survival and migration through the FAK–paxillin pathway. Together these give BPC-157 a well-described identity across the vascular, growth-factor and tissue-repair research strands.

BPC-157 is most frequently referenced alongside TB-500 (thymosin β-4) in the canonical "soft-tissue" research stack — the two act on distinct pathways (growth-factor / nitric-oxide signalling versus actin dynamics) that converge on the tissue-repair research model. See the BPC-157 + TB-500 research blend product page for the co-lyophilised research-stack variant.

The information provided here is a research-reference summary only. Elite AU Peptides makes no medical, therapeutic, performance, or human-use claim about this product. BPC-157 is not TGA-approved, is not a therapeutic good, and is supplied strictly for in-vitro and laboratory research use only. Researchers should consult the primary peer-reviewed literature for pathway data and protocol-specific reference values.

Reconstitute the lyophilised BPC-157 vial with bacteriostatic water for laboratory handling. Add the diluent slowly down the vial wall and swirl gently rather than shaking. The required volume depends on the protocol’s downstream assay requirements — a 5 mg vial reconstituted in 2 mL of bacteriostatic water yields a 2.5 mg/mL working stock; a 10 mg vial reconstituted in 5 mL yields a 2 mg/mL working stock. Adjust per protocol.

Store the lyophilised powder at −20°C, desiccated and protected from light; once reconstituted, store refrigerated at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles. Tamper-evident packaging; the batch label is the canonical reference for the certificate of analysis published in the lab-reports library.

Shop bacteriostatic water

Australia only. Free shipping over $100. Orders placed before 12pm AEST are dispatched the same business day from Australia.

30-day returns on unused product in original packaging, with prior approval.